1. Agrawal AK, Pragya R, Choudhary A, Gupta A, Sambasivaiah K, Mishra BK, Khaddar S, Kapoor A, Sotorasib–An inhibitor of KRAS p (2021) G12c mutation in advanced non-small cell carcinoma: a narrative drug review. Cancer Res Stat Treat 4(3):524
2. Alzahrani AS (2019) PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. In: Seminars in cancer biology, vol 59. Academic Press, pp 125–132
3. Ando K, Akimoto K, Sato H, Manabe R, Kishino Y, Homma T, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Sagara H (2020) Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: A systematic review and network meta-analysis. Cancers 12(4):942
4. Azizi M, Spiess PE (2018) Targeted therapy in penile cancer: a new treatment paradigm. Nat Rev Urol 15(1):5–6
5. Biersack B, Polat S, Höpfner M (2022) Anticancer properties of chimeric HDAC and kinase inhibitors. In: Seminars in cancer biology, vol 83. Academic Press, pp 472–486